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Abstract The liver has adapted to the inflow of ingested
toxins by the evolutionary development of unique regener-
ative properties and responds to injury or tissue loss by the
rapid division of mature cells. Proliferation of the paren-
chymal cells, i.e. hepatocytes and epithelial cells of the bile
duct, is regulated by numerous cytokine/growth-factor-
mediated pathways and is synchronised with extracellular
matrix degradation and restoration of the vasculature.
Resident hepatic stem/progenitor cells have also been
identified in small numbers in normal liver and implicated
in liver tissue repair. Their putative role in the physiology,
pathophysiology and therapy of the liver, however, is not yet
precisely known. Hepatic stem/progenitor cells also known
as “oval cells” in rodents have been implicated in liver tissue
repair, at a time when the capacity for hepatocyte and bile
duct replication is exhausted or experimentally inhibited
(facultative stem/progenitor cell pool). Although much more
hastobelearnedabout theroleofstem/progenitor cellsinthe
physiology and pathophysiology of the liver, experimental
analysis of the therapeutic value of these cells has been
initiated. Transplantation of hepatic stem/progenitor cells or
in vivo pharmacological activation of the pool of hepatic
stem cells may provide novel modalities for the therapy of
liver diseases. In addition, extrahepatic stem cells (e.g. bone
marrow cells) are being investigated for their contribution to
liver regeneration. Hepatic progenitor cells derived from
embryonic stem cells are included in this review, which also
discusses future perspectives of stem cell-based therapies for
liver diseases.
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Stem cells in liver regeneration
Physiological homeostasis of the liver
Under physiological conditions, as few as one out of 2000–
3000 hepatocytes divide to maintain the physiological liver
mass. Liver damage or loss of liver mass can however
extensively stimulate the regenerative capacity until the
tissue mass has been restored by the proliferation of mature
parenchymal liver cells (Fausto et al. 2006). Up to 75% of
surgically removed liver mass can be regenerated within
1 week in rodents (Michalopoulos and DeFrances 1997).
Accelerated parenchymal regeneration after necrogenic or
surgical loss of liver tissue principally originates from the
extensive proliferation of mature parenchymal liver cells
rather than from liver stem/progenitor cell proliferation. In a
young adult rat or mouse, approximately 95% of hepato-
cytes replicate during the first 3 days after partial
hepatectomy. This proportion drops to approximately 80%
in senescent rats (Tsanev 1975).
The newborn liver contains only diploid hepatocytes but
polyploidisation and binuclearity occurs rapidly after birth.
Fractionation of isolated adult rat hepatocytes based on cell
density has yielded subpopulations with “small” mononu-
cleated hepatocytes and “large” hepatocytes with higher
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e-mail: OTT-MHH@GMX.deploidy. Hepatocytes with higher ploidy have been shown to
reside predominantly in the perivenous areas and to contain
more DNA and to exhibit greater maturity. The “smaller”
mononucleated hepatocytes are locatedinthe periportalareas,
contain less DNA and exhibit greater growth factor respon-
siveness. The gradient of less complex cells with higher
proliferation potential (in vitro) in periportal areas and more
maturehepatocytesinperivenousareashasbeeninterpretedas
evidence for the existence of a physiological stem cell com-
partment (Sigal et al. 1995). The “streaming liver hypothe-
sis”, which suggests that the liver lobule is organised in a
similar way to the intestinal crypt by containing a stem cell
pool arising form the periportal area has, however, been dis-
proved by the observation that nearly all hepatocytes prolif-
erate as a response to injury, regardless of location and ploidy.
Although mature hepatocytes and cholangiocytes repre-
sent the first and most important resource for tissue repair,
experimental data support the hypothesis that the liver also
contains or activates a stem cell compartment (Doyle and
Ross 2003; Lechner and Habener 2003; Suzuki et al. 2002).
Resident hepatic stem/progenitor cells
Evidence for the existence and activation of a resident hepatic
stem/progenitor cells (rHSPC) compartment has been provid-
ed from various murine animal models of “oval cell”
proliferation (Alison et al. 1997; Fausto 2004;T h o r g e i r s s o n
1996). The general principle underlying oval cell activation
is based on a combination of liver injury and the inability of
hepatocytes to proliferate in response to damage. For ex-
ample, if a DNA-damaging agent is administered followed by
partial hepatectomy, mitosis of hepatocytes is blocked, and
oval-shaped cells emerge from the portal zone. These oval
cells play a facultative role in liver regeneration, i.e. they
contribute to tissue regeneration only in cases in which adult
hepatocyte proliferation is inhibited or exhausted (Fausto and
Campbell 2003).
A cell compartment that has not as yet been defined
gives rise to these rapid proliferating transient cells that
subsequently differentiate into mature hepatocytes and bile
duct cells. Anatomically, they arise from areas close to the
terminal biliary duct (canals of Hering) of the liver, although
additional locations have been described. To date, whether
oval cells pre-exist in the tissue or develop from other adult
cell types (i.e. bile duct cells) after an injury, is unknown. The
restricted potential to differentiate into hepatocytes and
cholangiocytes qualifies oval cells more as progenitor cells
rather than true stem cells. Cell lines with “non-hepatocyte”
phenotypes, which can function as lineage-generating pre-
cursors, have been derived from livers of rodents exposed to
toxic chemicals or carcinogens and from normal liver with no
histological evidence of stem/progenitor cell activation
(Azuma et al. 2003;T s a oe ta l .1984; Tsuchiya et al. 2007).
The dissection and classification of cell populations on
the basis of their molecular heterogeneity have become
fundamental working tools in cell biology. For example, the
differentiation state, lineage specificity or functional status
of a given haematopoietic cell population can be precisely
determined and communicated based on their antigenic and
molecular properties (Mason et al. 2002). In contrast to the
haematopoietic cell lineage, the molecular characterisation
of the stem cell compartments in solid organs still suffers
from the lack of specific markers that unambiguously label
all stem cells and only stem cells, enabling their prospective
identification, cultivation and propagation. For a long time,
this absence of tissue-specific stem cell markers has posed
challenges to the identification and isolation of the “true”
liver stem cell. A systematic understanding of the stem cell
compartment and their respective cell lineages, however, is
of fundamental importance for our understanding of phys-
iological liver regeneration and liver tissue repair after
injury and disease. A range of markers has been used to
characterise the rHSPC compartment including a host of
monoclonal antibodies against cytoskeletal proteins and
unknown surface antigens. However, few appropriate cell
surface markers that permit the fractionation of viable liver
cell sub-populations by fluorescence-activated cell sorting
exist. Some candidates have been suggested by a recent
report on fetal liver epithelial cells (Nierhoff et al. 2005).
Another report on adult rat liver cells describes six surface
markers unique to adult liver precursor cells, including
CD133 (Yovchev et al. 2007). Nevertheless, even the most
basic parameters of resident liver stem/progenitor cells, such
as their size, precise location within the liver and morphol-
ogy, are not yet known in vary species.
For this reason, the stem/progenitor compartment of the
liver is assumed to consist of cells with various phenotypes
and multiple molecular markers. Most of the markers have
beenidentifiedbyimmunohistochemistryfromrodentmodels
of oval cell activation. In multiple independent studies, these
oval cells have been shown to share molecular markers with
adult hepatocytes (albumin, cytokeratins 8 and 18), bile duct
cells (cytokeratins 7 and 19, OV-6, A6), fetal hepatoblasts
(AFP),andhaematopoieticstemcells(Thy-1,Sca-1,c-kit).In
a recently published mouse model with transgenic expression
of the green fluorescence protein (GFP) under transcriptional
control of nestin gene promoter and enhancer elements,
Gleiberman and co-workers (2005) have identified, in the
normal liver, GFP-marked cells at low frequencies with
characteristic properties of oval cells, indicating a pre-formed
stem/progenitor cell pool in the liver. Additional molecular
markers have been identified by genome-wide analysis of
mRNA expression in liver tissue and cells derived from
rodent injury models with oval cell activation.
Such studies are beginning to elucidate the molecular
markers and signalling pathways involved in stem cell/
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involving stromal-derived factor 1 alpha (SDF-1α) has
been shown to activate oval cells through SDF-1α/CXCR4
interactions (Hatch et al. 2002). Other molecular pathways
involving cytokines have been identified as mitogenic for
oval cells. In the CDE diet model of oval cell activation in
mice, the over-expression of tumour necrosis factor (TNF),
interleukin-6 (IL-6), oncostatin M and others correlates
with the rapid phase of oval cell expansion in the liver. The
cytokine TWEAK (TNF-related weak inducer of apoptosis)
may also specifically activate the rHSPC compartment in
mouse liver through binding of the FN-14 receptor, which
is expressed on the surface of biliary epithelial cells. Inter-
estingly, unlike TNF or IL-6, TWEAK does not induce the
proliferation of the mature hepatocytes and biliary duct
epithelial cells (Jakubowski et al. 2005).
Evidence from several laboratories suggests that hepatic
stem/progenitor cells express the “side population” (SP)-
phenotype similar to multipotent haematopoietic stem cells.
The SP-phenotype of haematopoietic stem cells in mice and
humans is largely determined by the expression of a protein
known as the ABCG2 (BCRP1), viz. ATP-binding cassette
transporter (Scharenberg et al. 2002). The SP-cells in liver
suspensions are phenotypically heterogeneous with subsets
of these cells expressing diverse markers of haematopoietic
cell lineages (Uchida et al. 2001). In animal models of
hepatic stem/progenitor cell (oval cell) activation, the
mRNA of the ABCG2 transporter increases over time in
liver tissue indicating an increasing proportion of hepatic
stem cells within the non-parenchymal fraction of cells with
the SP-phenotype (Shimano et al. 2003). From the data
available so far, we can conclude that cells characterised by
the SP-phenotype as the common marker account for most
of the stem cell activities in their respective organs.
Protocols for the isolation, culture and propagation of
resident liver stem/progenitor cells have been established
for several decades. Resulting cell lines have drawn
attention, both for their therapeutic potential and for their
usefulness in exploring the molecular events surrounding
liver development and regeneration. Oval cell lines have
mostly been derived from liver of rodents exposed to
chemicals and carcinogens. Non-hepatocyte epithelial cell
lines have also been propagated from normal livers without
evidence for oval cell activation. Resulting cell lines have
received the generic name “liver epithelial cell lines”.A sa n
example,postnatalmouselivercellscannowbeenrichedwith
clonogenic growth potential by using existing cell surface
markers (Li et al. 2006). The cells are isolated by single-cell
cloning and express liver progenitor cell markers and some
antigens shared by bone-marrow-derived haematopoietic
stem cells, such as c-Kit and Thy-1. When cultured as
aggregates in Matrigel, the mouse liver progenitor cells
differentiate into hepatocytes upon treatment with epithelial
growth factor (EGF) or differentiate into biliary lineage cells
upon treatment with hepatocyte growth factor (HGF). In the
presence of dimethylsulphoxide and Matrigel, the cells
acquire predominantly bile-lineage phenotypes. Upon trans-
plantation into CCl4-injured liver, engraftment into liver
parenchyma and differentiation into hepatocytes have been
demonstrated.
Most of the protocols to induce oval cells from murine
liver tissue involve treatment of the animals with carcin-
ogens and are thus not appropriate for the isolation of
respective human cell populations. Alternatively, Parent and
colleagues have established HepaRG cell lines with a dual
differentiation potential from a liver associated with chronic
hepatitis C infection (Cerec et al. 2007; Parent et al. 2004).
One recent study has reported the successful isolation of a
stem cell population from a normal adult human liver.
Unlike most of the other studies on oval/progenitor cells,
these isolated stem cells are closely related to mesenchymal
stem cells and do not express haematopoietic markers
(Herrera et al. 2006). So far, none of these protocols to
isolate human liver progenitor cells would fulfil the require-
ments for clinical application.
In the human liver, progenitor cell activation has been
associated with a variety of liver diseases and the number
of progenitor cells has been related to the severity of the
disease (Roskams et al. 2003). In parallel to our knowledge
of these rodent models, inhibition of the replication of
mature hepatocytes is also inhibited in human liver
diseases. Recently, hepatocytes have been shown to become
senescent, following telomere shortening, in the cirrhotic
stage of a wide variety of chronic human liver diseases
(Marshall et al. 2005; Wiemann et al. 2002). Probably, this
hepatocyte replicative senescence is in part the result of
ongoing proliferation during 20–30 years of chronic liver
disease. Chronic inflammation and the presence of growth
factors and DNA-damaging agents, such as reactive oxygen
species and nitrogen species, also play a role. Several
chronic human liver diseases display oval cell proliferation,
particularly primary biliary cirrhosis (Bisgaard et al. 2002;
Tan et al. 2002). Evidence is increasing that “progenitor
cell” proliferation is associated with the evolution of
hepatocarcinoma and cholangiocarcinoma (Alison and
Lovell 2005; Petersen 2001). However, whether oval cells
are simply a marker of carcinogenic disease states or
whether oval cells are at particular risk of transformation
still remains unclear.
Extrahepatic stem cells as a source for liver cells?
In the last few years, many reports have suggested that
extrahepatic stem cells participate in liver regeneration and
may be useful for treating many diseases (Alison et al. 2000;
Herzog et al. 2003; Lagasse et al. 2000; Petersen et al. 1999;
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independent groups has clearly shown that hepatocyte
replacement levels after bone marrow transplantation are
low (<0.01%), unless the bone-marrow-derived hepatocytes
have a selective growth advantage (Cantz et al. 2004;
Kanazawa and Verma 2003; Wagers et al. 2002). Further-
more, in most of the cases, fusion with host hepatocytes,
rather than transdifferentiation of extrahepatic cells, has been
described as the underlying principle (Alvarez-Dolado et al.
2003; Quintana-Bustamante et al. 2006; Vassilopoulos et al.
2003;W a n ge ta l .2003b; Willenbring et al. 2004). Appar-
ently, extrahepatic cells are not directly involved in liver
regeneration but may be a suitable tool to correct a metabolic
defect by fusion-mediated additive gene transfer. This will be
discussed at the end of the second section of this review.
(Stem) Cell-based therapies for liver disorders
Mature (adult) hepatocytes
Despite their restricted proliferation capacity in vitro, adult
hepatocytes show a high proliferation capacity in vivo.
Experiments with serial murine hepatocyte transplantations
in mice deficient in fumaryl-acetoacetate hydrolase (FAH
-)
havedemonstratedmorethan69celldoublingsora 7.3×10
20-
fold expansion (Overturf et al. 1997). About 30 years ago,
the first animal experiments showed isolated hepatocytes
suitable for the treatment of liver diseases. For example, the
Gunn rat is a model for UDP-glucuronosyl transferase
(UGT1A1) deficiency (Crigler-Najjar syndrome type I)
leading to high serum bilirubin levels. After transplantation
of primary adult hepatocytes into these animals, the bilirubin
level is markedly reduced, although not normalised (Matas
et al. 1976). Many other animal models for human liver
disorders have also been studied for the potential of hepa-
tocyte transplantation, including metabolic disorders such as
Wilson’s disease (Long-Evans cinnamon rats; Yoshida et al.
1996), tyrosinemia (FAH
- mice; Overturf et al. 1997),
hypercholesterolemia (Watanabe rabbit; Wiederkehr et al.
1990), intrahepatic cholestasis mdr3
-/- mice (De Vree et al.
1998), and ornithine transcarbamylase (OTC) deficiency
(spf-ash mice; Michel et al. 1993).
Meanwhile, a considerable number of patients treated for
metabolic disorders has been reported. In 1998, a 10-year-
old girl suffering from Crigler-Najjar syndrome type I was
treated with an infusion of 7.5×10
9 hepatocytes through the
portal vein for partial correction of the metabolic defect. By
11 months after transplantation, the need for daily photo-
therapy had decreased from 10–1 2ht o6 –7 h and lowered
the serum bilirubin from 450 μmol/l to 240 μmol/l (Fox et al.
1998). Under immunosuppression with tacrolimus, no signs
of rejection of the cells were observed. Despite the possibility
of repeated transplantation, a conventional liver transplanta-
tion was successfully performed 2.5 years after the cell
transplantation. Some other cases have been described in the
last few years, including a newborn boy with OTC
deficiency (Horslen et al. 2003), a 4-year-old girl with a
peroxisomal biogenesis defect (Refsum disease; Sokal et al.
2003) and a 47-year-old woman with glycogen storage
disease type 1a (Muraca et al. 2002). A recent review of Anil
Dhawan and colleagues summarises the outcome of 20
treated patients and ends with the conclusion that consider-
able progress has been made in developing the technique but
that hepatocyte transplantation is limited by the available
supply of liver tissue. Hepatocytes derived from stem cells
might provide alternative sources of cells in the future
(Dhawan et al. 2006).
Few studies on liver cell therapy for the treatment of
acute liver failure in humans have the intention to bridge
the gap until patients until receive orthotopic liver trans-
plantations (Bilir et al. 2000; Schneider et al. 2006; Strom
et al. 1997). The main challenges for this approach are the
number of transplanted cells, the availability of freshly
prepared cells or the quality of cryoconserved cells and the
need for immunosuppression to prevent the rejection of the
transplanted cells. The last-mentioned point may become
more important than has been previously considered because
liver failure itself gives a high risk for septic complications,
which will be aggravated by immunosuppressive drugs.
Fetal hepatic progenitor cells
Recent studies with transplantations of fetal liver cells show
a higher proliferation capacity in the host liver than after
treatment with adult hepatocytes. In rats, clusters of 500–
1000 cells have been observed after fetal liver cell trans-
plantation and partial hepatectomy for stimulation of liver
regeneration. This equals an expansion of approximately
nine- to ten-fold after 6 months and a repopulation efficacy
of 6%–10%. If the rats have been pre-treated with
retrorsine, which blocks endogenous hepatocyte prolifera-
tion capacity before transplantation, a repopulation of as
high as 80% is achieved (Sandhu et al. 2001). After trans-
plantation of mouse fetal liver cells into 14– to 20-day-old
uPA-mice, which develop sub-acute liver failure caused by
the expression of the uroplasminogen activator (uPA) under
the control of the albumin promoter, donor-derived regen-
eration nodules were also detectable. They show a mature
hepatic phenotype as established by gene expression
profiling and a functional integration within in the first
4 weeks after transplantation (Cantz et al. 2003). Thus, fetal
liver cells may be suitable for overcoming the limitations in
engraftment and to allow a functional correction of the
disease phenotype, at least in disorders in which a low
percentage of cells with a correct genotype are sufficient.
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liver cells in the treatment of acute liver failure, modest
clinical improvement (Habibullah et al. 1994). Neverthe-
less, ethical issues to be considered if fetuses from late
abortions are necessary, and as for adult hepatocytes, the
need for immunosuppressive regimens will cause additional
problems.
Bone-marrow-derived cells
Eight years ago, B. Petersen, M. Alison and N. Theise were
among the first to describe the contribution of bone-
marrow-derived cells to liver regeneration. They analysed
sex-mismatched bone marrow and liver transplantations in
rats (Petersen et al. 1999), mice (Theise et al. 2000a) and
humans (Alison et al. 2000; Theise et al. 2000b) and were
able to show Y-chromosome-positive hepatocytes as single
cells or small clusters in the recipients.
Since the liver is the site for haematopoiesis at fetal
stages, haematopoietic stem cells might have the capability
to generate oval cell and parenchymal liver cells also in the
adult organ. In adults, the haematopoietic stem cells reside
in the bone marrow and have the ability to reconstitute all
haematopoietic cell lineages and to rescue lethally irradiat-
ed animals from bone marrow failure. Some of the markers
of haematopoietic stem cells, for example, c-kit, stem cell
factor (SCF) and Thy-1, are also expressed by the putative
residenthepatic stem/progenitor cells,whichoccur inthe liver
in response to several modes of injury as described above
(Fujio et al. 1994; Petersen et al. 1998, 2003). The first
reports about the formation of hepatocytes from haemato-
poietic stem cells in vivo came up in the late nineties and
suggested a wider plasticity of HSC than previously known.
The most convincing study was reported by E. Lagasse,
who demonstrated that haematopoietic stem cells (c-kit
+,
lin
-, Sca
+ and thy-1
low) give rise to functional hepatocytes
(Lagasse et al. 2000). The presence of large donor-derived
regeneration nodules can rescue mice from a lethal disease
of hereditary tyrosinemia, and functional assays have been
performed to identify and characterise the differentiated
cells. However,this particular model provides strong selec-
tion pressure on FAH-positive transplanted cells regulated
by repeated withdrawal of the compound NTBC (nitro-
trifluoro-methylbenzol-cyclohexanedione). Two lessons
were to be learned from his experiments. First, a high
selection pressure seemed to be necessary for repopulation
of a significant part of the liver with bone-marrow-derived
cells. Second, only a few cells gave the origin of the small
numbered but big sized regeneration nodules. Hence, two
years later, a comment of C. Mitchell and N. Fausto
summarises the role of bone-marrow-cell-derived liver
regeneration as: “rare, but promising” (Mitchell and Fausto
2002). So far, bone-marrow-derived cells have been used
only in non-controlled, non-randomised phase-I clinical
trials with a few patients suffering from chronic liver
diseases (Gordon et al. 2006; Terai et al. 2006). The authors
of these studies report an improvement of liver function in a
subset of patients, but these findings should be interpreted
carefully, as no control group was investigated. Autologous
CD133-positive bone marrow cells have been used to
improve the expansion of the residual liver lobe after portal
vein embolisation of tumor-bearing liver segments (am
Esch et al. 2005; Furst et al. 2007). Compared with a
control group, the increase in the liver volume is signifi-
cantly higher in the CD133-treated group but whether this
effect is attributable to cell engraftment and transdifferentia-
tion, to regenerative factors secreted by the transplanted
cells or to the method of cell preparation remains unclear.
Therefore, we speculate that bone marrow transplanta-
tion without expansion of the resulting donor hepatocytes
might not be therapeutically effective and that sophisticated
methods have to be applied to increase the number of stem-
cell-derived hepatocytes in the recipient liver. Three main
determinants could influence the role of stem cells in liver
repopulation: (1) the time course, severity and type of liver
tissue injury, (2) the expression of homing factors for stem
cells in the recipient liver and (3) a sufficient number of
circulating haematopoietic stem cells at the time of tissue
regeneration. Cantz et al. (2004) have tested two of the
three variables by application of the liver toxin carbon
tetrachloride (CCl4) to induce liver tissue injury and by
mobilising the bone marrow stem cells into the peripheral
blood by granulocyte colony-stimulating factor (G-CSF).
The authors have found no evidence of an effect of CCl4
and/or stem cell mobilisation regimens on the usual low
transdifferentiation rate of bone marrow cells into hepato-
cytes (Cantz et al. 2004). In another study, Kanazawa and
Verma (2003) have addressed the effect of acute and
chronic liver injury on bone-marrow-derived hepatocyte
formation. They have used three different models of liver
injury: (1) CCl4 application to induce toxic liver damage, (2)
the albumin-urokinase transgenic mouse model with sub-
acute intrinsic liver failure and (3) the hepatitis B transgenic
mouse representing a chronic liver disease model. Bone-
marrow-derived cells from GFP- or β-galactosidase trans-
genic mice were transplanted into irradiated sex-mismatched
mice. Even 47 weeks after transplantation, only a low num-
ber of transgene-marked bone-marrow-derived hepatocytes
was detected in any of the recipient mice (Kanazawa and
Verma 2003).
In the meantime, several groups have made progress in
elucidatingthemechanismoftheobservedstemcellplasticity,
which was first considered to be transdifferentiation. Several
studies have clearly shown that the correction of the FAH
-/-
phenotype is attributable to the fusion of bone-marrow-
derived cells with host hepatocytes (Alvarez-Dolado et al.
Cell Tissue Res (2008) 331:271–282 2752003; Vassilopoulos et al. 2003;W a n ge ta l .2003b). In the
most detailed study (Willenbring et al. 2004), several
controversial points have been addressed: (1) no fusion of
mature hepatocytes has been observed, which strongly
disproves a transdifferentiation-followed-by-fusion theory,
(2) bone marrow reconstitution is not necessary to induce
fusion of host hepatocytes and granulocyte-macrophage
progenitors, (3) even after intrasplenic transplantation of in
vitro differentiated mature macrophages, fusion between
donor and host cells is observed. The authors conclude that
the administration of fusogenic macrophages to the damaged
organ represents a targeted therapeutic strategy (Willenbring
et al. 2004). Quintana-Bustamante and co-workers (2006)
have applied CCl4 over 3 months followed by injection of
pegylated G-CSF for up to 3 weeks in mice that had been
irradiated and reconstituted with GFP-marked bone marrow.
The authors have demonstrated that the observed bone-
marrow-derived hepatocytes do not originate from the
differentiation of haematopoietic stem cells but are generated
by fusion. The number of bone-marrow-derived hepatocytes
is much lower than previously reported and only marginally
increased by chronic liver injury and mobilisation of bone
marrow stem cells (Quintana-Bustamante et al. 2006).
Thorgeirsson and Grisham (2006) have recently
reviewed 77 published reports that examine the ability of
haematopoietic cells to generate hepatocytes in the liver.
They conclude that haematopoietic cells do not trans-
differentiate into hepatocytes and contribute little to
hepatocyte formation under physiological or pathological
conditions. Although fusion clearly is the only established
way to generate hepatocytes from blood stem cells so far,
the debate concerning whether this is the only mechanism
has not yet been decided (Thorgeirsson and Grisham 2006).
In contradiction to these findings, other groups report
bone-marrow-derived liver cells without fusion of haemato-
poietic donor and host liver cells. In a sophisticated study
with the Cre/lox recombinase system, Harris et al. (2004)
have shown that bone-marrow-derived epithelial cells occur
in the liver, lung, and skin without cell fusion. Whether
these cells develop by the transdifferentiation of haemato-
poietic stem cells or by the differentiation of multipotent
epithelial precursors existing in the bone marrow prepara-
tion remains to be investigated. The derivation of multi-
potent adult progenitor cells during the culture of bone
marrow cells has been well examined by the group of C.
Verfaillie (Reyes et al. 2001) and the feasibility of in vivo
(Schwartz et al. 2002) and in vitro (Jiang et al. 2002)
differentiation into hepatocytes has been demonstrated.
However, the data remain preliminary and functional
analyses in terms of transplantation experiments have not
yet been performed.
Another group has studied the conversion of haemato-
poietic stem cells into liver cells in vitro by using a co-
culture system in which the stem cells are separated from a
CCl4-damaged liver section (Jang et al. 2004). The authors
again conclude that microenvironmental cues rather than
fusion are responsible for the germ layer switching of the
haematopoietic stem cells. Moreover, highly enriched male
haematopoietic stem cells were injected, via the tail vein,
into irradiated female mice in vivo. A subgroup of mice
received CCl4 additionally to increase liver injury. Confocal
serial imaging showed mostly diploid (XY) or tetraploid
(XXYY) male cells expressing hepatic marker proteins
such as albumin and only a few cells with a fusion-related
karyotype (XXXY). Aurich et al. (2007) have reported that
human bone-marrow-derived mesenchymal stem cells can
be pre-differentiated towards a hepatic phenotype in vitro,
before transplantation into RAG2-mice. The authors have
demonstrated the presence of single human hepatocyte-like
cells with no signs of fusion in this experimental setting
(Aurich et al. 2007).
Different explanations can be presented for these con-
tradictory results. First, the chronic damage in the FAH
-/-
mice causes chromosomal instability (Jorquera and Tanguay
2001) that may facilitate fusion events. Second, the type
and extent of liver damage (metabolic disorders, irradia-
tion, toxic injury, ischaemia) may play a role. Third, it may
be important to transplant very early haematopoietic pro-
genitors in a sufficient number to see conversion into epi-
thelial cells.
These hypotheses may also explain the failure of other
groups to show a significant impact of bone-marrow-derived
cells on liver regeneration in mice (Cantz et al. 2004;
Kanazawa and Verma 2003; Wagers et al. 2002). Although
the age of donor mice, the severity of liver damage between
different mouse strains (Shi et al. 1997) and the experimental
settings are not similar in these published experiments, they
clearly show that the use of bone-marrow-derived cells for
the treatment of liver diseases is far from clinical application
and that additional basic research on reprogramming is
needed.
Human umbilical cord blood
Some researchers have argued that stem cells derived from
bone marrow or cord blood of human origin exhibit higher
plasticity than the respective mouse or rat cells (Di Campli
et al. 2004;I s h i k a w ae ta l .2003;K a k i n u m ae ta l .2003;
Newsome et al. 2003; Tanabe et al. 2004; Turrini et al. 2005;
Wang et al. 2003a). Indeed, several groups have detected
high rates of human hepatocyte formation without signs of
fusion in xenogenic murine transplantation models. In 2003,
Newsome and his colleagues demonstrated that human
umbilical cord-blood (hUCB)-derived cells could differentiate
into hepatocytes after transplantation into immunodeficient
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mononuclear hUCB cells were transplanted into sub-lethally
irradiated NOD/SCID mice and the livers were analysed
after 1, 4, 6 and 16 weeks for the presence of human
hepatocytes. The percentage of human compared with mouse
hepatocytes reached an average of 0.011% after 16 weeks,
whereas no additional damage to the host liver was inflicted,
other than the sub-lethal irradiation before reconstitution of
the bone marrow. The absence of mouse and human DNA
together within single cells ruled out fusion as the underlying
mechanism for the stem cell plasticity and once again
favoured the transdifferentiation theory. From these experi-
ments, the questions arose as to whether the hUCB had an
even higher plasticity than bone-marrow-derived stem cells
or whether the immunodeficient NOD/SCID mice facilitated
the transdifferentiation of transplanted stem cells. To
investigate these points, mononuclear bone marrow cells
from enhanced-GFP transgenic mice and hUCB cells were
transplanted, with the same protocol, into NOD/SCID mice
and, in addition, hepatocellular damage with CCl4 was
administered (Sharma et al. 2005). No donor-derived cells
were detectable after transplantation of murine bone marrow
cells but some single hepatocytes and even a few clusters of
human origin were detected in the hUCB-transplanted mice.
However, marker expression was incomplete in these cells.
Serial sections of the recipient livers revealed a mixed
expression of mouse and human antigens indicating fused
“chimerical” mouse/human hepatocytes in the recipient
mouse livers (Sharma et al. 2005).
In 2004, human cord-blood-derived multipotent cellswere
described by Kögler and colleagues( 2004). These “unre-
stricted somatic stem cells” (USSC) could differentiate into
hepatocytes after transplantation into a pre-immune fetal
sheep model (Kögler et al. 2004). Subsequently, the fusion
of USSC with host hepatocytes was ruled out by using
species-specificpolymerasechainreactiononmicro-dissected
tissue samples (G. Kögler, personal communication).
The infusion of particular subsets of haematopoietic
stem cells (Liv8
-) may be of therapeutic benefit, even in the
absence of hepatocyte formation. According to one recently
published study, haematopoietic stem cells can partially
revert CCl4-induced fibrosis of the mouse liver through the
activation of the matrix metalloproteinase-9 and improves
the survival of the animals (Sakaida et al. 2004).
Embryonic stem cells
Embryonic stem (ES) cells can be maintained in a state of
pluripotency for long periods of time and can be grown in
large numbers (Boiani and Scholer 2005; Keller 1995;
Rathjen and Rathjen 2001). Under appropriate culture
conditions, ES cells spontaneously form all somatic cell
types of the adult body, including endoderm-derived cells
and hepatic progenitors. The non-directed differentiation of
ES cells can be achieved through the formation of embryoid
bodies (EB), which contain cells representing lineages
derived from the three germ layers: ectoderm, mesoderm
and endoderm. Subsequent inoculation of the EB-derived
cells onto adherent matrices facilitates differentiation into
hepatocyte-like cells in the presence of a variety of growth
factors, cytokines and hormones, such as hepatocyte growth
factor (HGF), fibroblast growth factor (FGF) and dexameth-
asone. Significant progress has been made in identifying
factors and developing protocols to enforce the differentiation
of ES cells into cells of the hepatocyte lineage (Chinzei et al.
2002;C h o ie ta l .2002; Gouon-Evans et al. 2006; Hamazaki
et al. 2001; Heo et al. 2006; Ishizaka et al. 2002; Jones et al.
2002; Kania et al. 2004; Miyashita et al. 2002; Teratani et al.
2005; Yamada et al. 2002; Yin et al. 2002). Hamazaki and
co-workers (2001) were among the first to generate a high
percentage of hepatocyte precursors from murine ES cell
cultures in the presence of growth factors. Miyashita et al.
(2002) and Kania et al. (2004) have subsequently published
differentiation protocols that direct the maturation of the
primitive ES cells towards cells with a distinct and mature
hepatic phenotype and that result in a high percentage of
ES hepatic progenitor cells (ES-HPC) in culture. Bone
morphogenetic protein-4 has recently been identified as
mediating an important signal in the development of cells
with a hepatic phenotype from ES cells (Gouon-Evans
et al. 2006).
The transplantation of contaminating pluripotent ES cells
carries the risk of teratoma formation and may mask or
inhibit the formation of hepatocytes and normal liver tissue
from ES-HPC. Cell-sorting techniques utilising either anti-
bodies directed against lineage-specific surface markers of
the desired cell population or cell-type-specific expression
of reporter genes have been established to eliminate
contaminating undifferentiated ES cells and thus to reduce
the risk of teratoma formation (Klug et al. 1996). Another
strategy to prevent teratoma formation is to implant the
ES-HPC into devices for bio-artificial liver support (Soto-
Gutierrez et al. 2006).
Hepatocyte formation derived from sorted ES-HPC has
recently been demonstrated in fumaryl-acetoacetate-deficient
(FAH
-/-) and uroplasminogen-activator transgenic MUP-
uPA/SCID mice, clearly indicating the potential of ES-HPC
for cellular therapies (Gouon-Evans et al. 2006; Heo et al.
2006). The rate of hepatocyte and liver tissue formation,
however, is much lower than that previously reported for
transplanted primary adult hepatocytes or fetal hepatoblasts
(Fig. 1). The reduced efficacy of hepatocyte and liver tissue
formation may have been attributable to lower primary
engraftment rates of the ES-HPC into the recipient liver,
incomplete differentiation or a combination of both.
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The transplantation of mature hepatocytes into humans over
the past 20 years has provided insights regarding the way in
which to treat human liver disease by cellular therapies. The
shortage of adult hepatocytes from donated organs has
given a strong impetus to the search for alternative cellular
resources. Stem-cell-based therapies for the liver, however,
have not yet reached the stage of clinical application.
Progenitor cell lines derived from normal human liver tissue
may be an alternative source of hepatocytes for therapy in the
future, although isolation, cultivation and propagation proto-
cols will have to be improved substantially. Human fetal liver
progenitor cells have been shown to engraft and proliferate in
rodents and could eventually become an important source for
liver cell therapy, if fetal liver cells can be successfully
expanded in vitro. Currently, transplantation into FAH
-/- mice
is the only model in which haematopoietic cells have con-
tributed to liver repopulation to a degree relevant for clinical
application. The underlying mechanism is fusion with host
hepatocytes, providing an additive gene transfer, which
rescues the metabolic defect. However, the frequency of in
vivo fusion of macrophages and endogenous hepatocytes is
below the requirements of most clinical applications, which
lack a selection pressure as strong as that in the FAH
-/- model.
The application of stem cells in liver therapies seems to
be a promising approach for the treatment of liver diseases.
However, several issues still have to be addressed to fulfil
this promise. We need to identify, both inside and outside of
the liver, the stem cell candidates that are able to form
hepatocytes in vitro and functional liver tissue after
transplantation in vivo. The fundamental molecular path-
ways involved in the differentiation of hepatocytes and
cholangiocytes from stem/progenitor cells, the factors that
are responsible for in vitro differentiation of various stem
cells into hepatocytes, the mechanisms involved in the
fusion of macrophages and hepatocytes and the aspects that
can potentially enhance these mechanisms need to be
studied in more detail. Finally, the role of hepatic stem/
progenitor cells in response to liver injury and in the normal
regeneration of liver must be elucidated further. With future
progress in research into stem cell biology, hepatic stem/
progenitor cells, embryonic and adult extrahepatic stem
cells should provide great potential for the treatment of
liver disorders.
Appendix
Fig. 1 Transplantation of ES-derived hepatic progenitor cells.
Embryonic stem cells can be differentiated towards a hepatic
progenitor cell-phenotype (ES-HPC). After transplantation of wild-
type ES-HPCs into immunosuppressed FAH
-/- mice, engraftment of
single cells (arrowheads) and formation of regeneration nodules after
ES-HPC proliferation (arrows) can be observed. The 3-amino-9-
ethylcarbazole-substrate staining of the cells demonstrates the pres-
ence of FAH-enzyme activity in the FAH
-/- recipient liver. Bar 25 μm
Fig. 2 Stem cells in liver regeneration and therapy. Under physio-
logical conditions, the division and proliferation of mature hepatocytes
maintain hepatocyte number, i.e. liver mass. In humans and rodents, a
75% partial hepatectomy can be regenerated by this capacity. Under
experimental conditions or carcinogenic changes, hepatocyte prolifer-
ation can be blocked. In this case, resident hepatic stem/progenitor
cells (rHSPC) proliferate and differentiate into hepatocytes. The recent
literature suggests the existence of an extra-hepatic stem cell pool that
contributes to liver regeneration. Bone-marrow-cell-derived cells, e.g.
mesenchymal stem cells, can give rise to hepatocytes in distinct
experimental settings. Cell transplantation of adult and fetal hepato-
cytes has been established at the stage of phase-I clinical trials in
patients with metabolic liver disorders or acute liver failure.
Embryonic-stem-cell-derived hepatic cells are currently being inves-
tigated as a transplantable cell source in order to overcome limitations
in cell number and tissue compatibility for future therapeutic
strategies
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